Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
When a maize plant is attacked by the fungus Ustilago maydis, tumor-like tissue growths occur at the site of infection. How the pathogen causes this response in its host has long been unknown. But a ...
Coherus Oncology (CHRS) announced the publication of preclinical and clinical biomarker research in Molecular Cancer Therapeutics describing the ...
-Data show CCR8 target is present with high prevalence and density in many solid tumors- ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...
In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback